BACKGROUND: It has been reported, but not proven, that perioperative blood transfusions have a detrimental effect on the survival of patients undergoing surgery for lung cancer. STUDY DESIGN: and methods: A prospective study was carried out on the patients undergoing lobectomy for stage I lung cancer at our department from 1995 to 2000. The criteria for exclusion included previous cases of malignancy, autoimmune diseases, and any other relevant comorbidity. RESULTS: Two hundred eighty-one patients were observed, 24.6% of whom received transfusions. The only significant difference between the transfused and nontransfused patients was their preoperative hemoglobin (Hb) concentration (12.5 +/- 1.20 g/dL vs 13.3 +/- 1.22 g/dL, p < 0.001). The disease-free interval of the transfused patients was significantly lower than that of the nontransfused patients (53% vs 78% at 73 months, p < 0.005), as was also the case for actuarial survival (52% vs 71% at 73 months, p < 0.02). Blood transfusion was significantly predictive of tumor relapse according to the Cox model adjusted for the T state, preoperative Hb concentration, sex, age, histologic type, and grading (hazard ratio, 2.3; p = 0.017). CONCLUSIONS: Our data show that perioperative blood transfusion is significantly correlated to worse prognosis in patients undergoing surgery for stage I lung cancer.
BACKGROUND: It has been reported, but not proven, that perioperative blood transfusions have a detrimental effect on the survival of patients undergoing surgery for lung cancer. STUDY DESIGN: and methods: A prospective study was carried out on the patients undergoing lobectomy for stage I lung cancer at our department from 1995 to 2000. The criteria for exclusion included previous cases of malignancy, autoimmune diseases, and any other relevant comorbidity. RESULTS: Two hundred eighty-one patients were observed, 24.6% of whom received transfusions. The only significant difference between the transfused and nontransfused patients was their preoperative hemoglobin (Hb) concentration (12.5 +/- 1.20 g/dL vs 13.3 +/- 1.22 g/dL, p < 0.001). The disease-free interval of the transfused patients was significantly lower than that of the nontransfused patients (53% vs 78% at 73 months, p < 0.005), as was also the case for actuarial survival (52% vs 71% at 73 months, p < 0.02). Blood transfusion was significantly predictive of tumor relapse according to the Cox model adjusted for the T state, preoperative Hb concentration, sex, age, histologic type, and grading (hazard ratio, 2.3; p = 0.017). CONCLUSIONS: Our data show that perioperative blood transfusion is significantly correlated to worse prognosis in patients undergoing surgery for stage I lung cancer.
Authors: M Gierth; A Aziz; H M Fritsche; M Burger; W Otto; F Zeman; M T Pawlik; E Hansen; M May; S Denzinger Journal: World J Urol Date: 2014-02-08 Impact factor: 4.226
Authors: M Jawad Latif; Kay See Tan; Daniela Molena; James Huang; Matthew J Bott; Bernard J Park; Prasad S Adusumilli; Valerie W Rusch; Manjit S Bains; Robert J Downey; David R Jones; James M Isbell Journal: J Thorac Cardiovasc Surg Date: 2019-02-12 Impact factor: 5.209
Authors: Juan P Cata; Cristina Gutierrez; Reza J Mehran; David Rice; Joseph Nates; Lei Feng; Andrea Rodriguez-Restrepo; Fernando Martinez; Gabriel Mena; Vijaya Gottumukkala Journal: Cancer Cell Microenviron Date: 2016
Authors: Gregory D Jones; Raul Caso; Jae Seong No; Kay See Tan; Joseph Dycoco; Manjit S Bains; Valerie W Rusch; James Huang; James M Isbell; Daniela Molena; Bernard J Park; David R Jones; Gaetano Rocco Journal: Eur J Cardiothorac Surg Date: 2020-07-01 Impact factor: 4.191